News

Hemanext Signs Agreement with Hemara Bio

Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announced that it has entered into an exclusive distribution agreement with Hemara Bio in Dubai, United Arab Emirates (UAE) to bolster its sales capabilities across the Gulf Countries strengthening its relationships with key blood centers and clinicians in the region.

Hemanext has entered into an exclusive distribution agreement with Hemara Bio to bring the Hemanext ONE® Red Blood Cell (RBC) Processing and Storage System to UAE, Qatar, Kuwait and the Kingdom of Saudi Arabia (Gulf Cooperation Council (GCC) Region). This agreement is in response to the increasing need for safe and efficient blood transfusions, especially for patients who rely on frequent transfusions due to chronic diseases or trauma.

The Hemanext ONE RBC Processing and Storage system limits oxygen, the fuel for oxidative damage, providing a higher quality blood product.1,2,3 It has the potential to benefit all patients requiring transfusion for chronic conditions, such as thalassemia4, sickle cell disease (SCD)5, and myelodysplastic syndromes (MDS),6 as well as those in need of critical transfusions during post-traumatic surgery and other medical procedures.7

Pr. Mohamed Yassin, Professor of Hematology and Head of Hematology at Hamad Medical Corporation, Doha (Qatar), stated, “I am pleased to see the partnership between Hemanext and Hemara Bio, which will bring the innovative hypoxic transfusion system to the GCC Region. This technology addresses a significant unmet need, particularly for patients suffering from hemoglobinopathies, such as sickle cell disease and thalassemia. For these patients, traditional transfusion methods have limitations in optimizing red blood cell efficacy. Hypoxic RBCs processed from The Hemanext ONE RBC Processing and Storage system offers a potential new way to improve oxygen delivery and overall patient outcomes, which is essential in this region where hemoglobinopathies are prevalent. I look forward to seeing the impact this will have on our patients and on transfusion practices throughout the GCC.”

“We are excited about our partnership with Hemara Bio as it opens a pathway towards access to Hemanext ONE and hypoxic red blood cells for patients throughout the GCC Region. Our Hemanext ONE system has the potential to help improve cost of care and overall quality of life for those living with the burden of transfusion therapy. In Hemara Bio, we are confident to have found a partner that will be able to swiftly bring Hemanext ONE to blood banks,” stated Andrew Dunham, CEO of Hemanext.

Mohamed Algamal, CEO of Hemara Bio, said, “We are thrilled to be working alongside the Hemanext team to bring this exciting innovation in blood transfusion therapy to clinicians and patients in the GCC Region. We have deep experience bringing innovative therapies to patients in need throughout the GCC Region and see the Hemanext ONE® system as such a unique innovation that we would like to make available to patients.”

About Hemanext

Hemanext is a privately held medical technology company based in Lexington, MA that is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy. The company’s research and development efforts center on the study of hypoxically stored RBCs. The company’s aim is to significantly improve the quality of stored RBCs worldwide.

About Hemara Bio

Hemara Bio specializes in providing advanced hematological solutions tailored for the Middle East and Africa region. With a focus on rare genetic diseases and cutting-edge therapies, the company is dedicated to improving healthcare standards and ensuring access to innovative treatments.

Visit Hemarabio.com to learn more about the Company.

About Hemanext ONE®

In Europe, Hemanext ONE is CE marked for the processing and storage of CPD/PAGGSM Red Blood Cells, Leukocytes Reduced (LR RBC) that have been prepared and processed with the HEMANEXT ONE® system within 24 hours of collection. In the GCC Region, marketing authorization for Hemanext ONE is in preparation for submittal for approval by the local regulatory authorities. The HEMANEXT ONE® system limits the O2 and CO2 levels in the storage environment. Red Blood Cells Leukocytes Reduced, O2/CO2 Reduced may be stored for up to 42 days at 1-6°C. HEMANEXT ONE® is used for volumes no greater than 350 ml of LR RBC.3

Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration.

HEMANEXT ONE creates hypoxic RBCs, RBCs that have been processed to reduce oxygen and carbon dioxide content of RBCs and to maintain this level throughout storage up to 42 days.3 Hypoxic RBCs have demonstrated positive impacts on multiple in vitro metrics of RBC quality in preclinical studies.8,9 Clinical studies are underway to determine the impact of hypoxic RBCs on patient outcomes and estimate potential cost savings from expected improvements in care and reductions in transfusion volumes.10

Hemanext Media Contact
Daan Kok
Head of Business Development and Strategy
daan.kok@hemanext.com
+41782061460

  1. Rabcuka J, Blonski S, Meli A, et al. Metabolic reprogramming under hypoxic storage preserves faster oxygen unloading from stored red blood cells. Blood Adv. 2022;6(18):5415-5428. doi: 10.1182/bloodadvances.2022007774
  2. Reisz JA, Wither MJ et al. Oxidative modifications of glyceraldehyde 3-phosphate dehydrogenase regulate metabolic reprogramming of stored red blood cells. 2016;128(12): e32-42.
  3. HEMANEXT ONE® (Blood container set used to process and store CPD/PAGGSM Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced) [EU Instructions for Use]. Lexington, MA: Hemanext Inc.
  4. Farmakis D, Porter J, Taher A, et al. 2021 Thalassemia International Federation Guidelines for the management of transfusion-dependent thalassemia. 2022;6:8.
  5. Chou S, Alsawas M, Fasano R, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4:2.
  6. Germing U, Oliva E, Hiwase D, and Almeida A. Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS: current and emerging strategies. 2019;3(6). doi: 10.1097/HS9.0000000000000314
  7. American College of Surgeons. ACS TQIP massive transfusion in trauma guidelines. ACS TQIP. 2014; https://www.facs.org/media/zcjdtrd1/transfusion_guildelines.pdf.
  8. Yoshida T, Blair A, D’Alessandro A, et al. Enhancing uniformity and overall quality of red cell concentrate with anaerobic storage. Blood Transfus. 2017;15(2):172-81.
  9. Yoshida T, McMahon E, Croxon H, et al. The oxygen saturation of red blood cell concentrates: The basis for a novel index of red cell oxidative stress. Transfusion. 2022;62(1):183-193. doi: 10.1111/trf.16715.
  10. Reikvam H, Hetland G, Ezligini F, et al. Safety of hypoxic red blood cell administration in patients with transfusion-dependent hematological malignancies: An interim analysis. Transfus Apher Sci. 2023; doi: 10.1016/j.transci.2023.103755.
Previous
Next

By producing higher quality RBCs, the Hemanext ONE system has the potential to enable fewer and more effective transfusions for patients. I am truly excited by the possibility of bringing this improved red blood cell replacement therapy to populations in the U.S. that have been waiting for a transformative technology like this one.

Dr. Philip C. Spinella
Professor, Department of Surgery and Department of Critical Care Medicine at University of Pittsburgh

We value our partnership with Hemanext to enhance blood product quality and availability. Hemanext ONE has the potential to strengthen the resiliency of the blood supply, and this FDA authorization is a significant milestone to that end.

Ralph Vassallo, MD, FACP
Executive Vice President, Chief Medical and Scientific Officer of Vitalant

The Hemanext ONE system offers promise to improve the treatment landscape for patients burdened by transfusions and could be an essential step towards performing fewer and better transfusions. Having long championed Hemanext’s transformative initiatives, I eagerly anticipate witnessing the positive influence, right here in the United States, on the advancement of transfusion therapy quality.

Paul M. Ness, MD
Former Director, Division of Transfusion Medicine at Johns Hopkins University and board member of Hemanext

By deoxygenating red cells and maintaining them in their hypoxic state throughout storage, the resulting red cells experience less oxidative stress and oxidative damage, have improved metabolism, and are also more deformable leading to improved micro vascular profusion and less hemolysis.

Dr. Steven Spitalnik, MD
Co-Director of the Laboratory of Transfusion Biology, Colombia University

The preclinical data by Williams et al. show anaerobically stored RBCs achieve multiple clinically important functional resuscitation goals, with a smaller volume of fluid and the FDA benchmark of 24-hour RBC recovery. I look forward to the clinical trials in bleeding patients.

John Holcomb, MD, FACS
University of Alabama at Birmingham

I have had several patients who have received Hemanext hypoxic blood, and several of the patients have personally said thanks for having been given the opportunity and also that they have felt better after transfusion with hypoxic blood compared to conventional transfusion. One must of course be careful not to attach too much importance to such observations, but I would still like to mention that there has been a remarkable tendency towards this.

Håkon Reikvam, MD, PhD
Professor, Department of Clinical Science, University of Bergen, Norway

CONTACT US  |  TERMS OF USE

PRIVACY & COOKIES POLICY

This website may contain information on products or uses of those products that are not authorized in all countries or regions. Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration. In Europe Hemanext ONE is CE marked which allows the medical device to be placed in the market in the EEA. Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Hemanext, Hemanext ONE, and the logos are registered trademarks of Hemanext, Inc. © 2026 Hemanext, Inc. All rights reserved.

Contact Us